RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection and reinfection in a seroepidemiological workplace cohort in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.04.21256609
DO 10.1101/2021.05.04.21256609
A1 Emilie Finch
A1 Rachel Lowe
A1 Stephanie Fischinger
A1 Michael de St Aubin
A1 Sameed M. Siddiqui
A1 Diana Dayal
A1 Michael A. Loesche
A1 Justin Rhee
A1 Samuel Berger
A1 Yiyuan Hu
A1 Matthew J. Gluck
A1 Benjamin Mormann
A1 Mohammad A. Hasdianda
A1 Elon R. Musk
A1 Galit Alter
A1 Anil S. Menon
A1 Eric J. Nilles
A1 Adam J. Kucharski
A1 on behalf of the CMMID COVID-19 working group and the SpaceX COVID-19 Cohort Collaborative
YR 2021
UL http://medrxiv.org/content/early/2021/05/06/2021.05.04.21256609.abstract
AB Identifying the extent of SARS-CoV-2 reinfection is crucial for understanding possible long-term epidemic dynamics. We analysed longitudinal PCR and serological testing data from a prospective cohort of 4411 US employees in four states between April 2020 and February 2021. We conducted a multivariable logistic regression investigating the association between baseline serological status and subsequent PCR test result in order to calculate an odds ratio for reinfection. We estimated an adjusted odds ratio of 0.09 (95% CI: 0.005 – 0.48) for reinfection, implying that the presence of SARS-CoV-2 antibodies at baseline is associated with around 91% reduced odds of a subsequent PCR positive test. This suggests that primary infection with SARS-CoV-2 provides protection against reinfection in the majority of individuals, at least over a sixth month time period. We also highlight two major sources of bias and uncertainty to be considered when estimating reinfection risk, confounders and the choice of baseline time point, and show how to account for both in our analysis.Competing Interest StatementGA is a founder of Seromyx Systems Inc., a company developing platform technology that describes the antibody immune response. GA's interests were reviewed and are managed by Massachusetts General Hospital in accordance with their conflict of interest policies. MJG, SB, DD, YH, JR, EP, BM, ASM, and ERM are employees of Space Exploration Technologies Corp. All other authors have declared that no conflict of interest exists.Funding StatementAJK was supported by Wellcome Trust (grant: 206250/Z/17/Z) and NIHR (NIHR200908). EF was funded by the Medical Research Council (grant number MR/N013638/1), RL was funded by a Royal Society Dorothy Hodgkin Fellowship. The work was also supported by the Translational Research Institute for Space Health through NASA Cooperative Agreement (NNX16AO69A), the Massachusetts Consortium on Pathogen Readiness (MassCPR), the NIH (3R37AI080289-11S1, R01AI146785, U19AI42790-01, U19AI135995-02, U19AI42790-01, 1U01CA260476-01), and the Musk Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Western Institutional Review Board. The use of de-identified data and biological samples was approved by the Mass General Brigham Healthcare Institutional Review Board. All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode to reproduce the figures and simulation analysis presented can be found at https://github.com/EmilieFinch/covid-reinfection. The data that support the findings of this study are available on request by email. The data are not publicly available due to their containing information that could compromise the privacy of research participants.